Literature DB >> 11245437

Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

Y Gökmen-Polar1, N R Murray, M A Velasco, Z Gatalica, A P Fields.   

Abstract

Protein kinase C (PKC) has been implicated in colon carcinogenesis in humans and in rodent models. However, little is known about the specific role of individual PKC isozymes in this process. We recently demonstrated that elevated expression of PKC betaII in the colonic epithelium induces hyperproliferation in vivo (N. R. Murray et al., J. Cell Biol., 145: 699-711, 1999). Because hyperproliferation is a major risk factor for colon cancer, we assessed whether specific alterations in PKC betaII expression occur during azoxymethane-induced colon carcinogenesis in mice. An increase in PKC betaII expression was observed in preneoplastic lesions (aberrant crypt foci, 3.7-fold) compared with saline-treated animals, and in colon tumors (7.8-fold; P = 0.011) compared with uninvolved colonic epithelium. In contrast, PKC alpha and PKC betaI (a splicing variant of PKC betaII) expression was slightly decreased in aberrant crypt foci and dramatically reduced in colon tumors. Quantitative reverse transcription-PCR analysis revealed that PKC mRNA levels do not directly correlate with PKC protein levels, indicating that PKC isozyme expression is likely regulated at the posttranscriptional/translational level. Finally, transgenic mice expressing elevated PKC betaII in the colonic epithelium exhibit a trend toward increased colon tumor formation after exposure to azoxymethane. Taken together, our results demonstrate that elevated expression of PKC betaII is an important early, promotive event that plays a role in colon cancer development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245437

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Hydrophobic protein in colorectal cancer in relation to tumor stages and grades.

Authors:  Lay-Chin Yeoh; Chee-Keat Loh; Boon-Hui Gooi; Manjit Singh; Lay-Harn Gam
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.

Authors:  Wen-Liang Kuo; Jing Liu; Helena Mauceri; Everett E Vokes; Ralph Weichselbaum; Marsha Rich Rosner; Ezra Eddy Wyssam Cohen
Journal:  Mol Cancer Ther       Date:  2010-09-28       Impact factor: 6.261

3.  Protein kinase C isozymes as therapeutic targets for treatment of human cancers.

Authors:  Alan P Fields; Nicole R Murray
Journal:  Adv Enzyme Regul       Date:  2008-03-18

Review 4.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

5.  Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.

Authors:  Jianxiong He; Canhua Huang; Aiping Tong; Bin Chen; Zhi Zeng; Peng Zhang; Chunting Wang; Yuquan Wei
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

6.  PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1.

Authors:  Marybeth A Pysz; Olga V Leontieva; Nicholas W Bateman; Joshua M Uronis; Kathryn J Curry; David W Threadgill; Klaus-Peter Janssen; Sylvie Robine; Anna Velcich; Leonard H Augenlicht; Adrian R Black; Jennifer D Black
Journal:  Exp Cell Res       Date:  2009-02-14       Impact factor: 3.905

Review 7.  Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.

Authors:  Alan P Fields; Roderick P Regala
Journal:  Pharmacol Res       Date:  2007-05-05       Impact factor: 7.658

8.  Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression.

Authors:  Nicole R Murray; Justin Weems; Ursula Braun; Michael Leitges; Alan P Fields
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

9.  Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.

Authors:  Christopher D Willey; Dakai Xiao; Tianxiang Tu; Kwang Woon Kim; Luigi Moretti; Kenneth J Niermann; Mohammed N Tawtawy; Chad C Quarles; Bo Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-10       Impact factor: 7.038

10.  A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.

Authors:  Piotr Jasinski; Brandon Welsh; Jorge Galvez; David Land; Pawel Zwolak; Lori Ghandi; Kaoru Terai; Arkadiusz Z Dudek
Journal:  Invest New Drugs       Date:  2007-10-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.